Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines

British Journal of Dermatology

Volumn 158, Issue 3, 2008, Pages 496-504

  Sorolla, A ^a   Yeramian, A ^a   Dolcet, X ^a   Perez De Santos A M ^a   Llobet, D ^a   Schoenenberger, J A ^a   Casanova, J M ^a   Soria, X ^a   Egido, R ^a   Llombart, A ^a   Vilella, R ^b   Matias Guiu, X ^a   Marti, R M ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Apoptosis; Cancer; Cell proliferation; Melanoma; Proteasome inhibitors

Indexed keywords

ALDEHYDE; ALLN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BROXURIDINE; CASPASE; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; DNA; EPOXOMICIN; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; MELANOMA; MORTALITY; PRIORITY JOURNAL; SKIN CANCER; WESTERN BLOTTING;

APOPTOSIS; BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MELANOMA; PROTEASE INHIBITORS; PYRAZINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 39049092700     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08390.x     Document Type: Article

References (46)

1. Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2001 2 : 205 11.
2. Borner C, Schlagbauer Wadl H, Fellay I et al. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res 1999 9 : 347 50.
3. Yang J, Amiri KI, Burke JR et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006 12 : 950 60.
4. Satyamoorthy K, Chehab NH, Waterman MJ et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 2000 11 : 467 74.
5. Fernandez Y, Verhaegen M, Miller TP et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005 65 : 6294 304.
6. Wilk S, Orlowski M. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J Neurochem 1983 40 : 842 9.
7. Meng L, Mohan R, Kwok BH et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999 96 : 10403 8.
8. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002 7 : 9 16.
9. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumour agents. Cancer Res 1999 59 : 2615 22.
10. Vilella R, Benitez D, Mila J et al. Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003 106 : 626 31.
11. Vilella R, Benitez D, Mila J et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004 53 : 651 8.
12. Mayorga ME, Sanchis D, Perez de Santos AM et al. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res 2006 16 : 127 35.
13. Bahi N, Zhang J, Llovera M et al. Switch from caspase-dependent to caspase-independent death during heart development: essential role of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes. J Biol Chem 2006 281 : 22943 52.
14. Gross A, Jockel J, Wei MC et al. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998 17 : 3878 85.
15. Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005 65 : 6282 93.
16. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997 91 : 479 89.
17. Robertson JD, Orrenius S, Zhivotovsky B. Review: nuclear events in apoptosis. J Struct Biol 2000 129 : 346 58.
18. Wang X, Yang C, Chai J et al. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science 2002 298 : 1587 92.
19. Otera H, Ohsakaya S, Nagaura Z et al. Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J 2005 24 : 1375 86.
20. Joza N, Susin SA, Daugas E et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001 410 : 549 54.
21. Arnoult D, Parone P, Martinou JC et al. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 2002 159 : 923 9.
22. Cregan SP, Fortin A, MacLaurin JG et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002 158 : 507 17.
23. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004 5 : 417 21.
24. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004 4 : 349 60.
25. Palombella VJ, Rando OJ, Goldberg AL et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994 78 : 773 85.
26. LeBlanc R, Catley LP, Hideshima T et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002 62 : 4996 5000.
27. Nagy K, Szekely-Szuts K, Izeradjene K et al. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res 2006 12 : 133 42.
28. Markovic SN, Geyer SM, Dawkins F et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005 103 : 2584 9.
29. Amiri KI, Horton LW, LaFleur BJ et al. Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (Velcade, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004 64 : 4912 18.
30. Munshi A, Kurland JF, Nishikawa T et al. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther 2004 3 : 985 92.
31. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 2006 66 : 7598 605.
32. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006 12 : S2376 83.
33. Schumacher LY, Vo DD, Garban HJ et al. Immunosensitization of tumour cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006 176 : 4757 65.
34. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004 10 : 3839 52.
35. Freudlsperger C, Thies A, Pfuller U et al. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells. Anticancer Res 2007 27 : 207 13.
36. Jiang W, Mikochik PJ, Ra JH et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007 67 : 1221 7.
37. Vivier M, Jarrousse AS, Bouchon B et al. Preliminary studies of new proteasome inhibitors in the tumour targeting approach: synthesis and in vitro cytotoxicity. J Med Chem 2005 48 : 6731 40.
38. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006 95 : 961 5.
39. Joazeiro CA, Anderson KC, Hunter T. Proteasome inhibitor drugs on the rise. Cancer Res 2006 66 : 7840 2.
40. Daniel KG, Kuhn DJ, Kazi A et al. Anti-angiogenic and anti-tumour properties of proteasome inhibitors. Curr Cancer Drug Targets 2005 5 : 529 41.
41. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992 69 : 119 28.
42. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006 281 : 11923 32.
43. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001 412 : 95 9.
44. Susin SA, Lorenzo HK, Zamzami N et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999 397 : 441 6.
45. Arnoult D, Gaume B, Karbowski M et al. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J 2003 22 : 4385 99.
46. Dumont C, Durrbach A, Bidere N et al. Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult. Blood 2000 96 : 1030 8.